Redpoint Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Redpoint Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$389K	Sell	3,662 -1,426	-28%	-$145K	0.06%	380
2022 Q2	$496K	Hold	5,088	–	–	0.06%	376
2022 Q1	$477K	Buy	5,088 +1,391	+38%	+$118K	0.05%	426
2021 Q4	$315K	Sell	3,697 -172	-4%	-$15.8K	0.03%	562
2021 Q3	$371K	Hold	3,869	–	–	0.03%	526
2021 Q2	$377K	Hold	3,869	–	–	0.03%	529
2021 Q1	$376K	Hold	3,869	–	–	0.03%	513
2020 Q4	$371K	Sell	3,869 -347	-8%	-$33.5K	0.04%	432
2020 Q3	$405K	Sell	4,216 -10,444	-71%	-$1.21M	0.04%	402
2020 Q2	$1.79M	Buy	14,660 +7,509	+105%	+$830K	0.1%	237
2020 Q1	$619K	Buy	7,151 +5,105	+250%	+$500K	0.04%	391
2019 Q4	$220K	Buy	+2,046	New	+$214K	0.01%	580

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redpoint Investment Management's NBIX Position: Q3 2022 in Review

Redpoint Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 28% in Q3 2022, selling an estimated $145K and leaving 3,662 shares worth $389K. The position accounts for 0.06% of the portfolio, ranked #380.

Redpoint Investment Management first reported a position in NBIX in Q4 2019 and has held it in 12 quarters since. The position peaked at $1.79M in Q2 2020. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

Redpoint Investment Management held 3,662 shares of Neurocrine Biosciences worth $389K as of Q3 2022.
Redpoint Investment Management sold 1,426 Neurocrine Biosciences shares in Q3 2022, an estimated $145K.
Neurocrine Biosciences made up 0.06% of Redpoint Investment Management's portfolio in Q3 2022, its #380 holding.
Redpoint Investment Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 12 quarters since.
Redpoint Investment Management's Neurocrine Biosciences position peaked at $1.79M in Q2 2020.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Redpoint Investment Management's 13F filing for Q3 2022, filed 14 Oct 2022.